<DOC>
	<DOCNO>NCT00022685</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody epratuzumab locate tumor cell either kill deliver tumor-killing substance without harm normal cell . PURPOSE : Phase III trial determine effectiveness epratuzumab treat patient low-grade non-Hodgkin 's lymphoma respond chemotherapy rituximab .</brief_summary>
	<brief_title>Epratuzumab Treating Patients With Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine safety epratuzumab patient rituximab-refractory low-grade follicular B-cell non-Hodgkin 's lymphoma . - Confirm convenient administration drug patient population . - Determine efficacy drug term objective response rate patient . - Determine duration response time progression patient treat drug . OUTLINE : This multicenter study . Patients receive epratuzumab IV 15-60 minute day 1 , 8 , 15 , 22 . Patients follow every 8 week 10 month every 3 month 4 year . PROJECTED ACCRUAL : Approximately 30-100 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm lowgrade follicular Bcell nonHodgkin 's lymphoma Small cleave cell OR Mixed cell The follow ineligible : Primary CNS lymphoma HIV lymphoma Richter 's lymphoma Bulky disease ( single mass great 10 cm ) Pleural effusion positive cytology lymphoma Failed prior standard chemotherapy nonHodgkin 's lymphoma Refractory least 1 prior treatment rituximab Disease progression failure achieve objective response within 6 month begin rituximab therapy At least 1 bidimensionally measurable lesion At least 1.5 cm CT scan NOTE : A new classification scheme adult nonHodgkin 's lymphoma adopt PDQ . The terminology `` indolent '' `` aggressive '' lymphoma replace terminology `` low '' , `` intermediate '' , `` high '' grade lymphoma . However , protocol us former terminology . PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 60100 % ECOG 02 Life expectancy : At least 4 month Hematopoietic : Absolute granulocyte count least 1,500/mm^3 Platelet count least 50,000/mm^3 Hemoglobin least 8 g/dL Transfusion independent Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) * Alkaline phosphatase less 2 time ULN* AST less 2 time ULN* NOTE : *Unless lymphomarelated Renal : Creatinine great 1.5 time ULN unless lymphomarelated Other : No malignancy within past 5 year except squamous basal cell skin cancer carcinoma situ cervix No serious condition infection would preclude study participation Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 3 month study participation PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics At least 12 week since prior autologous stem cell transplantation No prior radioimmunoconjugate therapy Chemotherapy : See Disease Characteristics No 4 prior treatment regimen At least 4 week since prior chemotherapy Endocrine therapy : At least 2 week since prior corticosteroid No concurrent steroids Radiotherapy : See Biologic therapy At least 4 week since prior radiotherapy target lesion Surgery : At least 4 week since prior major surgery unless recover Other : At least 4 week since prior experimental therapy No concurrent investigational therapeutic agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2003</verification_date>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
</DOC>